953780-20-6

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(5-Bromo-pyridin-2-yl)-ethylamine is used as a building block for the synthesis of drug molecules, taking advantage of its chiral properties to create compounds with specific biological activities.
Used in Organic Chemistry:
(R)-1-(5-Bromo-pyridin-2-yl)-ethylamine is used as a reagent in various chemical reactions, contributing to the formation of new compounds with potential applications in different fields.
Used in Synthesis of Chiral Compounds:
(R)-1-(5-Bromo-pyridin-2-yl)-ethylamine is used as a key component in the synthesis of other chiral compounds, leveraging its non-superimposable mirror image to produce molecules with distinct properties and applications.

Upstream product

• 159533-68-3 2-(1-hydroxyethyl)-5-bromopyridine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 871723-90-9 1-(5-bromopyridin-2-yl)ethan-1-amine 

Relevant academic research and scientific papers

Straight from the bottle! Wine and juice dicarboxylic acids as templates for supramolecular cage self-assembly

Two imine based supramolecular cages are able to self-assemble in the presence of a complex mixture like wine or fruit juices. Taking advantage of templating agents present in these mixtures the systems are able to form and to selectively encapsulate dicarboxylic systems present in the mixtures. This capability has been exploited to develop molecular systems able to report the enantiomeric excess and composition of (a)chiral dicarboxylic acids in fruit juices and wines using 1H-NMR. This journal is

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.